Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
It targets both the GLP-1 receptor and the GIP receptor
it is not for unsupervised self-administration
In addition, in vitro models of primary human adipose stem cells, researchers detected intracellular fat content and quantitative expression of early and mature adipocyte markers (PPAR, FABP4, and HSL), demonstrating that glucagon can significantly reduce adipocyte differentiation, inhibit adipocyte proliferation and adipogenesis
Czechia BPC-157 purity confirmed at 99.2 % TB-500 purity confirmed above 99.8 % Assay content verified at 7.36 mg BPC-157 Assay content verified at 6.11 mg TB-500 Molecular ion mass identified at 1418 Da and 4963 Da Endotoxin level below 0.001 EU/mg No detectable heavy metals or microbial contamination Dual peptide research blend For research use only not for human or veterinary use For laboratory research only
GLP-1 medications may be appropriate for: Adults with type 2 diabetes Individuals with obesity (BMI 30) Individuals with overweight (BMI 27) plus weight-related conditions Patients with insulin resistance or metabolic syndrome They are not cosmetic weight-loss drugs and should not be used casually
10.1016/j.bbrc.2011.05.155 47 FarkasG.KirlyZ.SolymosiF
US$ 20.99
US$ 23.78
US$ 27.56
US$ 22.24
US$ 21.00
US$ 20.12
US$ 26.40
US$ 23.97
US$ 27.65
US$ 21.60
